ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
hepa82
|
48 |
13K |
2 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
13K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
hepa82
|
48 |
13K |
1 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
13K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Quarterly Appendix 4C and Activities Report
|
|
hepa82
|
48 |
13K |
0 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
48
|
13K
|
0
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
6 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
45
|
11K
|
6
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
6 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
45
|
11K
|
6
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
8 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
45
|
11K
|
8
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
1 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
49
|
14K
|
1
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
0 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
49
|
14K
|
0
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
0 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
49
|
14K
|
0
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
4 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
45
|
11K
|
4
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
4 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
45
|
11K
|
4
|
|
ASX - By Stock
|
APX |
Re:
APX Charts
|
|
hepa82
|
997 |
318K |
0 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
997
|
318K
|
0
|
|
ASX - By Stock
|
APX |
Re:
APX Charts
|
|
hepa82
|
997 |
318K |
1 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
997
|
318K
|
1
|
|
ASX - By Stock
|
G1A |
Re:
Ann: Appointment of Voluntary Administrators
|
|
hepa82
|
50 |
27K |
8 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
50
|
27K
|
8
|
|
ASX - By Stock
|
TNC |
Re:
Ann: TNC announces $5M institutional placement
|
|
hepa82
|
60 |
23K |
2 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
60
|
23K
|
2
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
6 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
45
|
11K
|
6
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Trading Halt
|
|
hepa82
|
45 |
11K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
45
|
11K
|
4
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Acquisition of TrialsWest Group
|
|
hepa82
|
2 |
871 |
8 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
2
|
871
|
8
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
3 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
49
|
14K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
hepa82
|
49 |
14K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
49
|
14K
|
0
|
|
ASX - By Stock
|
RHT |
Re:
Ann: Collaboration with Micron, Inc.
|
|
hepa82
|
10 |
2.0K |
2 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
10
|
2.0K
|
2
|
|
ASX - By Stock
|
OPL |
Re:
Ann: Opyl receives non-binding offer for its Opin business
|
|
hepa82
|
14 |
3.2K |
2 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
14
|
3.2K
|
2
|
|
ASX - By Stock
|
OPL |
Re:
Ann: Opyl receives non-binding offer for its Opin business
|
|
hepa82
|
14 |
3.2K |
3 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
14
|
3.2K
|
3
|
|
ASX - By Stock
|
AMD |
Re:
AMD General Discussion
|
|
hepa82
|
316 |
126K |
2 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
316
|
126K
|
2
|
|
ASX - By Stock
|
AMD |
Re:
AMD General Discussion
|
|
hepa82
|
316 |
126K |
4 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
316
|
126K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Dimerix to Present at Euroz Hartley Institutional Conference
|
|
hepa82
|
37 |
9.3K |
12 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
37
|
9.3K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
hepa82
|
247 |
73K |
0 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
73K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
hepa82
|
247 |
73K |
21 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
73K
|
21
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
hepa82
|
247 |
73K |
11 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
247
|
73K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
3 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
159
|
49K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
20 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
49K
|
20
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
11 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
49K
|
11
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
7 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
49K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
12 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
159
|
49K
|
12
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
19 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
159
|
49K
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
7 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
159
|
49K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
hepa82
|
159 |
49K |
19 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
159
|
49K
|
19
|
|
ASX - By Stock
|
DXB |
Re:
Dimerix (ASX: DXB) Discussion Thread
|
|
hepa82
|
626 |
197K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
626
|
197K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Interim Analyses of Clinical Trials
|
|
hepa82
|
185 |
48K |
9 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
185
|
48K
|
9
|
|
ASX - By Stock
|
ODE |
Re:
Ann: TARGETS GENERATED AT GASCOYNE EAST PROJECT
|
|
hepa82
|
10 |
3.2K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10
|
3.2K
|
5
|
|
ASX - By Stock
|
VMM |
Re:
Ann: Viridis Completes A$4.5 Million Placement
|
|
hepa82
|
239 |
51K |
2 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
239
|
51K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
98K |
37 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
98K
|
37
|
|
ASX - By Stock
|
VMM |
Re:
Ann: Viridis Completes A$4.5 Million Placement
|
|
hepa82
|
239 |
51K |
0 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
239
|
51K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
98K |
9 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
98K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
98K |
5 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
98K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
98K |
4 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
98K
|
4
|
|
ASX - By Stock
|
VMM |
Re:
Ann: Viridis Completes A$4.5 Million Placement
|
|
hepa82
|
239 |
51K |
0 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
239
|
51K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
hepa82
|
9.5K |
2.7M |
6 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
hepa82
|
272 |
98K |
23 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
272
|
98K
|
23
|
|
ASX - By Stock
|
EVN |
Re:
Ann: Annual Mineral Resource and Ore Reserves Statement
|
|
hepa82
|
2 |
1.1K |
6 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
2
|
1.1K
|
6
|
|